참고문헌 (12)

1. J. Infect. Dis. H. M. Blumberg 163 1279 1991 10.1093/infdis/163.6.1279 Blumberg, H. M., Caroll, D. D. J., Terry, P. and Wachsmuth, I. K., Rapid development of ciprofloxacin resistance in methicillin-susceptible and-resistantStaphylococcus aureus.J. Infect. Dis., 163, 1279-1285 (1991). 

   상세보기

2. Antimicrobial Agents and Chemotheraphy P. C. Fuchs 35 764 1991 10.1128/AAC.35.4.764 Fuchs, P. C., Barry, A. L., Pfaller, M. A., Allen, S. D. and Gerlach, E. H., Multicenter evaluation of thein vitro activities of three new quinolones, sparfloxacin, CI-960, and PD-131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.Antimicrobial Agents and Chemotheraphy, 35, 764-766 (1991). 

   상세보기

3. D. C. Hooper 53 1993 Quinolone antimicrobial agents Hooper, D. C. and Wolfson, J. S., Mechanisms of quinolone action and bactericidal killing, In Hooper, D. C. and Wolfson, J. S. (Eds.),Quinolone antimicrobial agents. American Society for Microbiology, Washington, D.C., 1993, pp. 53-75. 

4. Drugs D. C. Hooper 49 Suppl. 2 10 1995 10.2165/00003495-199500492-00004 Hooper, D. C., Quinolone mode of action.Drugs 49 (Suppl. 2), 10-15 (1995). 

   상세보기

5. Arch. Pharm. Res. M. Y. Kim 19 52 1996 10.1007/BF02976820 Kim, M. Y., Oh, J. I., Paek, K. S., Hong, C. Y., Kim, I. C. and Kwak, J. H.,In vitro activities of LB20304, a new fluoroquinolone.Arch. Pharm. Res. 19, 52-59 (1996). 

   원문보기 상세보기

6. National Committee for Clinical Laboratory Standards 1992 Methods for determining bactericidal activity of antimicrobial agents. M26-T National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents. M26-T. NCCLS, Villanova, Pa. (1992). 

7. National Committee for Clinical Laboratory Standards 1993 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically Third edition National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, Third edition; Approved standard M7-A3. NCCLS, Villanova, Pa. (1993). 

8. J. I. Oh 148 1995 Abstract F205 Abstracts of the 35th Interscience Conference on Antimicrobial agents and Chemotherapy, San Francisco, CA, 1995 Oh, J. I., Paek, K. S., Kim, M. Y., Seo, S. M., Lee, Y. H., Hong, C.-Y., Nam, D. H., Kim, Y. Z., Kim, I. C. and Kwak, J. H.,In vitro andin vivo antibacterial activities of LB20304, a new fluoronaphthyridone. InAbstracts of the 35th Interscience Conference on Antimicrobial agents and Chemotherapy, San Francisco, CA, 1995. Abstract F205, p. 148. American Society for Microbiology, Washington, D.C. (1995). 

9. Antimicrobial Agents and Chemotheraphy J. I. Oh 40 1564 1996 10.1128/AAC.40.6.1564 Oh, J. I., Paek, K. S., Ahn, M. J., Kim, M. Y., Hong, C. Y., Kim, I. C. and Kwak, J. H.,In vitro andin vivo evaluations of LB20304, a new fluoronaphthyridone.Antimicrobial Agents and Chemotheraphy, 40, 1564-1568 (1996). 

   상세보기

10. Arch. Pharm. Res. K. S. Paek 19 143 1996 10.1007/BF02976850 Paek, K. S., Ahn, M. J., Kim, M. Y., Kim, I. C. and Kwak, J. H., Factors affectingin vitro activity of LB 20304, a new fluoroquinolone.Arch. Pharm. Res. 19, 143-147 (1996). 

    원문보기 상세보기

11. Antimicrobial Agents and Chemotheraphy L. J. B. Piddock 38 163 1994 10.1128/AAC.38.2.163 Piddock, L. J. B., New quinolones and gram-positive bacteria.Antimicrobial Agents and Chemotheraphy, 38, 163-169 (1994). 

    상세보기

12. Antimicrobial Agents and Chemotheraphy M. C. Raviglione 34 2050 1990 10.1128/AAC.34.11.2050 Raviglione, M. C., Boyle, J. F., Mariuz, P., Pablos-Mendez, A., Cotes, H. and Merlo, A., Ciprofloxacin-resistant methicillin-resistantStaphylococcus aureus in an acute-care hospital.Antimicrobial Agents and Chemotheraphy, 34, 2050-2054 (1990). 

    상세보기